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Abstract. The ive-year evaluation of the Global Fund to ight HIV/AIDS, TB and malaria (GFATM) was 
carried out by a Consortium of several universities and institutions, led by a consulting irm based in 
Washington DC. The evaluation focused on three study areas: (i) organizational eficiency and effectiveness 
of the Global Fund, (ii)  effectiveness of the Global Fund partner environment, (iii) system effects of the 
Global Fund and impact of  increased funding on the level of response to the three diseases. The indings 
can be summarized as follows: the Global Fund has been successful in mobilizing additional funding and 
attracting new players. However, the demand-driven model used for allocation of funding is poorly adapted 
to epidemiological proiles with regard to population, persons at highest risk, and number of persons affected 
by the disease. The partner environment of the Global Fund, involving UN technical partners and institutions 
cooperating in development, has failed to produce planned results due to the weak institutional capacity of 
reci pients and health systems overall, as well as little synergy and coordination between international  partners. 
Increased inancial resources have allowed the rapid expansion of prevention and care services for the three 
diseases. Spectacular results have been achieved against malaria in Eastern African countries, but little 
 progress has been made in the collective effort to slow down the spread of HIV/AIDS. In preparation for the 
upcoming Replenishment Conference of the Global Fund and prior to any further decisions to expand the use 
of innovative inancing instruments for development, the author of this article calls the attention of policy-
makers to the need to ensure the development of accompanying strategies to increase the effectiveness and 
impact of these instruments at country level.
Keywords. Global Fund, health policies, partnerships, healthcare systems, evaluation, performance, aid 
 effectiveness, innovating inancing.
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The Global Fund to ight HIV/AIDS, Tuberculosis and 
Malaria Five-year Evaluation Policy Challenges
COMMENTARY
The Global Fund to ight AIDS, Tuberculosis and Malaria 
(GFATM) is a worldwide public/private partnership formed 
in 2002. Its aim is to contribute to achieving Millennium 
Development Goal 61 by attracting and  disbursing  additional 
 1 The Millennium Declaration sets out the 8 Millennium Development 
Goals, number 6 of which is to ‘Combat HIV/AIDS, malaria, and 
 other diseases’
public and private resources to prevent and treat three 
 diseases that kill over 6 million people worldwide each 
year2. The initiative’s context brought forward by UN 
 Secretary-General Koi Annan in 2001 is provided by the 
Millennium Declaration (1), the work done by the WHO 
Commission on Macroeconomics and Health (2), the UN 
 2 www.theglobalfund.org
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General Assembly Special Session on HIV/AIDS3, the 
 Abuja Declaration by African Heads of State to earmark 
15% of national budgets for health (3), and the Genoa G8 
meeting in 2001. The aim of these commitments is to con-
solidate a high level of political will and to boost national 
and international funding for health and the ight against 
these diseases in developing countries (inset 1). The Global 
Fund Executive Secretariat is based in Geneva, and the 
 organization has no country-level presence. The Local Fund 
Agent (LFA) is a  private country-level audit bureau respon-
sible for providing technical and inancial monitoring of 
program implementation by the principal recipient signing 
the grant agreement, with oversight by the Country Coordi-
nating Mechanism (CCM). The LFA is a local or regional 
irm appointed by  international bureaus selected at the 
time the programs were launched in 2002 under the Global 
Fund LFA competitive bidding process. At that time, the 
LFAs were Crown Agents, KPMG and Price Waterhouse 
Coopers. The LFA system has been the subject of a sepa-
rate  evaluation.
At the end of 2008, the outcome was as follows4: the 
 Global Fund accounted for a quarter of global funding for 
the ight against AIDS, and two-thirds of that was for tuber-
culosis and malaria.
It contributes to funding ARV access for nearly half of all 
patients receiving treatment in middle-income and low- 
income countries. In the period 2002-2009, 620 grant 
 contracts were signed with 140 countries. During this period, 
$16.2 billion of grant aid was approved, and $8.8 billion 
 actually paid. The breakdown across the three diseases was: 
55% for AIDS, 29% for malaria and 16% for tuberculosis. 
Africa received 57% of this funding (www.theglobalfund.
org). This continent is also the source of over 70% of new 
HIV infections (www.unaids.org).
In 2006, the Global Fund Board requested ‘a irst major 
evaluation of the Fund’s overall performance against its 
goals and principles after completion of at least one full 
grant  funding cycle (ive years)’. Three evaluation studies 
were commissioned by the Global Fund Technical Evalua-
tion  Reference Group (TERG), whose members are top-
level  experts on the three diseases, as well as representa-
tives from the community, universities, governments and 
nationalities from every continent. Its ex-oficio members 
include representatives of Stop TB, UNAIDS and Roll 
Back Malaria. The TERG is independent of the Global 
Fund Secretariat, and  reports directly to the Global Fund 
Board. The TERG set the evaluation terms of reference, 
ensured the independence and methodological quality of 
the evaluations, and monitored the quality of the reports. A 
Secretariat team of two was available to the TERG to 
 provide practical assistance. The purpose of these studies 
was to analyze three key aspects of Global Fund perfor-
mance: (i) institutional and organizational, (ii) partnership 
 3 UNGASS (United Nations General Assembly Special Session) 
http://www.ua2010.org/fr/UNGASS
 4 Global Fund Secretariat presentation to the GFATM Partnership 
 Forum in Dakar in December 2008.
eficiency and performance, and (iii) the impact of  funding 
on disease burden.
1 Global Fund evaluation methodology
1.1 Evaluation questions
The key questions can be summarized as follows on the basis 
of the three study areas (inset 2).
The evaluation was conducted by Macro International (inset 3)
The evaluation method and process were similar to those 
used for traditional evaluations: a review of documentation, 
interviews at international headquarter level, country-level 
interviews and visits, training sessions, and the set up of 
 technical and evaluation steering groups. Analyzing the 
 impact has raised many methodological questions, which we 
invite you to read (5). 
INSET 1
The guiding principles of the Global Fund are based on: 
(i) taking a global approach to combating these diseases, 
(ii) country-level deinition of the strategy for controlling 
these diseases with input from national public, private and 
community contributors working within the Country Coordi-
nating Mechanisms (CCMs), (iii) a balance between the three 
diseases and between regions, (iv) funding allocation based on 
program performance measured with indicators selected 
within the Global Fund monitoring and evaluation system 
 developed jointly by a number of partners (9), (v) national 
implementation supported and monitored inancially and 
technically by the Local Fund Agents (LFAs).
INSET 2
Study Area 1: Does the Global Fund as an organization 
(Board, Secretariat, TRP, LFAs) through both its policies 
and operations, relect the core principles, including acting 
as a  inancial instrument rather than an implementation 
agency, and furthering country ownership? In fulilling 
these principles, does the Global Fund as an organization 
perform in an  eficient and effective manner? This study 
was conducted in 2007, and the report was published the 
same year.
Study Area 2: How effective and eficient is the Global Fund 
partnership system in supporting HIV, malaria, and TB 
 programs at the global and country level? What are the wider 
effects of the Global Fund partnership on health systems? 
This study was conducted in 2007 and 2008, and the report 
published in June 2008.
Study Area 3: What is the Global Fund’s contribution to 
 reducing the burden of AIDS, tuberculosis and malaria? 
What has been the overall reduction in the burden of the 
three  diseases? This study was conducted in 2008 and 2009, 
and the report published in March 2009. In reality, it is the 
collective funding effort made by the Global Fund, the 
World Bank, PEPFAR and the (US) President’s Malaria Ini-
tiative that is analyzed across 18 countries covered by the 
impact study.
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INSET 3
The evaluation studies were conducted over the period 2006-
2009 by an evaluator appointed on the basis of an interna-
tional bidding process. The evaluator who was awarded the 
contract – Macro International – is a consulting irm based in 
 Washington DC. The evaluator brought together a  consortium 
of different universities and service providers for each study 
area. These included Johns Hopkins University,  Harvard 
School of Public Health, Washington University, Axios Inter-
national, Development Finance International (DFI), Macro 
International, the  Indian Institute for Health Management 
 Research, African Population and Health Research Centre, 
and a department of the WHO (the Health Information 
 Systems Department, which did most of the analysis of the 
indings for study area 3).
The evaluation reports (4 and 5) and the summary report 
for all three study areas (6) are available at http://www.the 
globalfund.org/en/terg/evaluations/5year/. In addition to 
these  documents, each country participating in the impact 
study produced its own evaluation report5. We will begin 
with the submission of the evaluation results, before 
 moving on to suggest a number of points for discussion. 
Only the results for study areas 2 and 3 are presented and 
discussed here, since the organizational structure of the 
Global Fund Secretariat was changed nearly three years 
 after publication of the irst study as a performance en-
hancement measure, rendering the majority of observations 
no longer relevant. 
The aim of the analysis offered here is not to criticize, as 
we are convinced that the Global Fund is a worthwhile 
route to funding the process of combating pandemic, on 
condition that funding are supported by relevant strategic 
mechanisms.
Our aim is: 1. to bring the relevant information and dis-
cussion to the attention of the French-speaking audience 
 concerned; and 2. to alert policy-makers to the need to 
 support global funding (i) through a strategic vision of the 
ight against AIDS, (ii) through a national and international 
expert evaluation suitable for a new public development aid 
governance structure and architecture, (iii) through initia-
tives to strengthen country-level capabilities in terms of 
performance administration, management, measurement 
and monitoring, and (iv) through effective mechanisms for 
promoting synergies between countries and fund providers 
to support health systems and the sector as a whole. The 
global fund evaluation reports contain many lessons for 
those who advocate the use of innovative funding for 
health or other sectors. It would be counterproductive to re-
invent the wheel, especially since we have limited resources 
at present.
 5 These reports produced by the 18 countries covered by the impact 
study are not available on the Global Fund website
2 The evaluation study results
2.1 Study to examine Global Fund partnerships at 
the global and country levels
The observations and recommendations made by the evalua-
tors focus on a number of themes relating to the expectations 
of the global fund partnership at the global level and how it is 
expressed within the Country coordinating mechanism 
(CCM). The following issues are addressed in particular: 
(i) the place of the Global Fund within the architecture of 
 international aid, (ii) the ability of countries to manage  Global 
Fund grants, (iii) the communication with countries and part-
ners, (iv) the required expertise, and (v) Global Fund project 
performance measurements.
The evaluator recognizes the ability of the Global Fund to 
attract and disburse very large volumes of funding at the 
 global level in the period from 2002 to 2007. From this point 
of view, one of the founding goals of the Global Fund was 
achieved during this period. The most important concept 
 regarding the place of the Global Fund within the wider archi-
tecture of international aid is that it should remain a funding 
institution and not become a technical agency. This presupposes 
that: (i) the strategies prepared by individual countries and 
adopted to combat the three diseases are relevant and that the 
funded initiatives are both effective and eficient, and (ii) the 
partnership with the United Nations agencies (the technical 
benchmark for the diseases), the stakeholders within individual 
countries and the development aid agencies, is working for 
the beneit of delivering the Fund’s programs.
The Global Fund must respect and facilitate the adoption 
of strategies by country stakeholders and ensure that the 
 priorities identiied by the CCMs align more accurately with 
the actual needs of countries. The Global Fund must develop 
a communications strategy that conveys a clearer under-
standing of its principles and mechanisms among those 
 approached to support its work. The GF is invited to develop 
a ‘global partnership framework’ that would deine the 
 precise roles, responsibilities and remits of partnership 
 members. The evaluators also stress the need to strengthen 
the capacity of sub-recipients of the Global Fund funding, 
not only in terms of training or funding provided via these 
organizations and/or associations for technical activities, but 
also in terms of developing the institutional and managerial 
capabilities of public, private and denominational partners, 
regardless of whether these are based in the capital or 
throughout the country. This would seem to be a fundamental 
recommendation if countries are to succeed in decentralizing 
the process of treating these diseases in the widest sense. 
Technical assistance for countries should not be limited 
 solely to the development phase of the funding proposal 
 submitted by the country: there is a substantial need for tech-
nical and managerial expertise all along the Global Fund 
funding implementation process.
Although the evaluator recognizes the contribution made 
by Global Fund programs to rekindling the interest of 
 countries and national managers in program performance, 
the performance system as designed by the Global Fund is 
identiied as an issue. In practical terms, the program 
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 monitoring/evaluation indicators are, in most cases, input 
and process indicators; the basic data used to measure 
 progress over time are either not present at the country level 
or are relatively unreliable; the system encourages the 
 generation of quantitative results, sometimes at the expense 
of quality, which could in turn limit the impact of prevention 
and treatment initiatives.
2.2 Study to examine the impact of joint funding  
on disease reduction
Since the services are spread relatively thinly,  
the likely impact is hard to measure
The impact study report and the evaluation results sum-
mary report stress the fact that the money attracted and 
 disbursed by the Global Fund, PEPFAR, the World Bank 
and the (US) President’s Malaria Initiative has extended 
the coverage of prevention, screening and treatment ini-
tiatives for all three diseases, and has had some effect on 
 malaria and AIDS- related mortality in some countries, 
 although the impact on reducing the incidence of AIDS is 
not clear because of:
(i) health information systems that are deicient to the point 
where they do not enable collection of the data required 
to  measure impact indicators, or even to track the preva-
lence of HIV infection in sentinel groups (pregnant 
women and blood donors) and high-risk groups (sex 
workers, drug users,  sexually-transmitted infection 
(STI) patients, etc.). On this basis, the evaluator recom-
mends that countries and the international community 
strengthen health information systems and the monito-
ring/evaluation capability of the health sector in order to 
facilitate country-level management of the sector and 
pave the way for future external evaluations.
(ii) the very modest results achieved by additional funding 
for AIDS prevention. A detailed reading of the chapter 
 devoted to AIDS in the third impact study once again 
reveals a relative failure in prevention and behavior 
change strategies, where higher levels of funding6 have 
not led to a reduction in HIV incidence, or even to 
 signiicant behavioral changes in most of the countries 
observed. This is partly due to the fact that prevention 
campaigns targeting the general population have been 
conducted in places where higher-risk groups should 
have been the priority targets. The reports state that, 
despite the progress made over time, initiative coverage 
still falls short of need. Blood and transfusion screening 
and  safety were not analyzed.
Funding allocation is not based on the level  
of disease burden
The evaluators working on the third Global Fund study area 
 observed that there are signiicant disparities in the way funding 
is allocated between countries with similar epidemic proiles, 
 6 One-third of Global Fund funding allocated to AIDS is focused on 
HIV prevention and screening
when considered from the point of view of population or number 
or people infected with HIV. In the period 2003-2006, Zambia 
received USD 11 per person, per year. The Democratic 
 Republic of Congo received little funding overall, while 
Rwanda, Haiti and Cambodia received the highest levels of 
aid per HIV-positive person.
Some countries with concentrated epidemics, such as 
 Kyrgyzstan and Moldavia, have received amounts dispropor-
tionate to their epidemic status: USD 500 per HIV-positive 
person. In January 2008, Zambia received $100 million from 
the Global Fund for a population of 11 million. The evaluator 
also found that less educated people in rural areas beneited 
less from the funding provided.
The impact study conducted into tuberculosis reveals no 
 signiicant change in the countries studied; a situation the au-
thors explain by referring to the fact that the anti-tuberculosis 
programs in these countries were already eficient and effec-
tive. In the case of malaria, the analysis reveals convincing 
results in terms of initiative coverage (provision of mosquito 
nets and insecticide impregnation), but little progress in ACT 
availability and distribution. The impact of the joint effort to 
combat malaria is very obvious in countries like Ethiopia, and 
can be seen in the reduction achieved in mortality rates of 
children under ive years old. In overall terms, the anti- malaria 
program is the one that presents the best results, with particu-
lar emphasis on the countries of East Africa, where morbidity 
and mortality levels are demonstrably lower; a trend which 
seems to be connected to control of the climate variable. The 
fact that this region was also subject to drought in 2009 is a 
cause for future vigilance.
The effects of Global Fund funding on health systems
Despite being asked to do so, the evaluators have not 
 described the structural effects of Global Fund funding on 
health systems in terms, for example, of laboratory services, 
the diagnosis of opportunistic infections, the biological 
benchmarking structure, the health sector inance structure 
in place in countries such as Rwanda, etc. Only the negative 
systemic effects hypothesis has been explored. 
In answering this question, the evaluators have chosen to 
look at what the mother and child health services have been 
able to provide over the evaluation period, compared with 
the period prior to the introduction of global initiatives (pre-
2003). The evaluator shows that in the countries analyzed 
(with  speciic  focus on Zambia, Rwanda and Malawi), 
 funding for maternal healthcare had also risen, but propor-
tionately less so than funding for AIDS, and that maternal 
healthcare services remained effective, even though the 
 coverage of initiatives was found to be  insuficient to achieve 
MDG 5 of reducing maternal mortality by three-quarters by 
2015. It does not appear that funding the ight against the 
three diseases has been achieved at the expense of other 
health expenditures. Furthermore, observed over the period 
2003-2006, infant mortality has not worsened in those 
 countries evaluated, where funding for the ight against the 
three diseases was  signiicant. We note that the decrease in 
mala ria-related infant mortality as a result of the success 
achieved by these programs in East Africa may in part 
 explain the good results seen in this area of healthcare in this 
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part of the  continent. In overall terms, the evaluator conirms 
that the provision of more money for the three  diseases has 
not  prevented health systems from continuing to supply 
 effective maternal and infant health services, and that there 
have therefore been no negative systemic effects as a result 
of ( additional) funding for these diseases in these  countries. 
We will show that the approach adopted by the  evaluators 
 imposes a number of limitations on the ability to answer 
 fully the  question regarding the systems effects of Global 
Fund  funding.
Conversely, the evaluators observed a form of donor 
 substitution in favor of the ight against tuberculosis, illus-
trated by the fact that bilateral funding was withdrawn when 
the global initiatives to combat tuberculosis irst appeared 
and, to a degree, took over that ight. Conversely, it does not 
seem that in countries where national accounts are available 
for healthcare services, that government funding to ight the 
three diseases had diminished, even though the quantity of 
external funding is undeniable, and may account for up to 
70% of total funding. The increase seems to be earmarked 
more in favor of AIDS and malaria, than tuberculosis, for 
 example. The evaluator observes that, where data are avail-
able, the countries of West Africa have received much less 
money than those of East Africa, “due partly to the fact that 
their epidemics are less widespread” (5). We note that it was 
not until the end of the ninth call for projects in 2009 that, for 
the irst time since the creation of the Global Fund in 2002, 
the amounts approved in favor of West and Central Africa 
exceeded those approved in favor of Southern Africa.
Basic health systems have widespread shortages 
Furthermore, according to the impact study, the district health 
assessments conducted showed that health centers have a 
shortage of everything: water, medical staff, protocols, 
 directives, medication, laboratory reagents, equipment and 
logistics resources, although in some countries where HIV 
tests are available, there are no hemoglobin measurements, or 
 glycemia or urine tests (5).
2.3 The Global Fund evaluation ive-year  
summary report
The summary of the three evaluation study areas  
covers 9 indings (inset 4)
On the basis of these observations and recommendations, the 
Global Fund Secretariat has put in place a series of provisions 
and – in some instances – has even responded in  advance of 
the analyses and recommendations. The performance-based 
funding system has been revised and the Secretariat has 
 prepared a Partnership Strategy which was approved by the 
Global Fund Board at its meeting in Ethiopia in November 
2009. The Global Fund has also joined in the work done by 
the Joint Platform for health systems strengthening, whose 
other members include the World Bank, WHO and the  Global 
Alliance for Vaccines and Immunisation (GAVI), in accor-
dance with the recommendations made by the Taskforce on 
Innovative International Financing for Health Systems7. The 
Global Fund has also taken the initiative of setting up a 
 working group to examine ways of making the transition 
from a demand-based model to a more rational model in 
which the allocation of Global Fund funding is based more 
squarely on the situation at country level (7).
The discussion that follows offers an analysis of the 
 relevance of some of the responses offered by the Global 
Fund on the one hand, and of the challenges not addressed 
by the evaluation on the other.
INSET 4
• The Global Fund has mobilized impressive 
amounts of funding to support its goal of ighting 
AIDS, tuberculosis and malaria.
• The collective effort made has resulted in increased 
coverage and availability of prevention and treatment 
services, although its impact on reducing the burden 
imposed by these diseases has yet to be seen.
• The failings seen in basic health systems are 
holding back the extension of AIDS, tuberculosis 
and malaria prevention and treatment services; in 
those areas where basic health services operate 
more effectively, the effects of programs to 
 combat these diseases are more evident. 
• The Global Fund promotes fairer access to 
 resources and services for women, the poorest in 
society, sexual minorities, those with the least 
education, rural populations, etc., but access to 
services by the most vulnerable population 
groups must be taken into consideration more 
closely when measuring grant performance.
• Until now, the system used to measure the per-
formance of Global Fund programs has focused 
on the outcomes achieved by the projects them-
selves, but considerable effort has yet to be 
made by the international community in order to 
ensure the more widespread strengthening of 
health  information systems that would enable 
more effective monitoring and evaluation of 
programs, both quantitatively and qualitatively.
• The Global Fund has succeeded in involving a 
broadly diverse base of national and international 
stakeholders, but this partnership model relies too 
heavily on goodwill, and should be structured 
around concrete commitments from the various 
parties involved. This commitment should extend 
to include strategies as well as health systems and 
the mobilization of technical  support.
• At the country level, the role of the CCMs has 
consisted essentially of working together in the 
 7 www. internationalhealthpartnership.net
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project funding submission phase. It is now 
 important to develop the scope of the CCMs by 
focusing on their role of providing  management, 
monitoring and technical expertise throughout 
the process of implementing programs funded 
by the Global Fund, and by adding real strength 
to the process by which individual countries 
adopt and push forward the ight against 
these diseases.
• The Global Fund has not developed a risk 
 management strategy with regard to administer-
ing the various levels of the very extensive fund-
ing it handles, and is exposed to the risk of poor 
funding application and misappropriation.
• The Global Fund governance model should be 
revised in such a way as to reposition the institu-
tion within the global architectural framework of 
health development aid, as well as within the 
public/private partnership that forms its structure. 
These revisions should extend to redeining the 
roles and responsibilities currently undertaken by 
the Global Fund Secretariat in Geneva, which 
may be better undertaken by partners. It is the 
 responsibility of the Global Fund Board to guide 
the Secretariat on issues regarding the strengthen-
ing or limitation of its missions, whether in terms 
of funding, health policy or development aid, in 
order to position the Global Fund more centrally 
within the context of the international develop-
ment aid architecture.
3 Discussion of the results of  
 the Global Fund evaluation
3.1 Limitations of the study examining  
the effectiveness of Global Fund partnerships
The contribution made by study area 2 of the Global Fund 
evaluation in analyzing the effectiveness of its partnerships is 
relative, since it repeats in 2008 the observations made in 
2003 and 2004 (8) regarding the governance of CCMs, the 
low-level capacity of sub-recipients, and the need for techni-
cal expertise, etc.
The evaluators observe that basic health services are short 
of most basic materials, except for tests, training, directives 
and AIDS medication. If basic commodities, like hemoglobin 
and urine testing, are not available in health centers where 
expensive tests are available, then why would it not be correct 
to talk about systemic effects in favor of AIDS at the expense 
of more everyday illnesses?
 With this in mind, it would have been reasonable to expect 
the evaluation steering committee to ask itself why the coun-
tries have not made much progress more than ive years after 
the initial studies’ indings were shared, and to bring forward 
new recommendations, especially in terms of governance. 
Study area 2 therefore suffered clearly from having been 
 unable to go beyond what was already known in order to 
 contribute something new to these discussions. From this 
point of view, the thoughts and contributions made by the 
countries themselves to the evaluation are not clear: despite 
the interviews that we know were conducted at the country 
level, readers of the evaluation reports have no idea regarding 
the thoughts and proposals of those working on the ground at 
the local level. The contribution of this study will ultimately 
be to encourage the Global Fund Secretariat to develop a 
partnership strategy clearly specifying the respective roles, 
responsibilities, and remits of each partner. What happens in 
the future will show whether this document and the resources 
that will accompany implementation of its  recommendations 
will be precise enough to facilitate partnership governance at 
the global scale and at the country level in such a way as to 
improve the eficiency of Global Fund programs.
3.2 The limitations of the evaluation  
on systemic effects
In addressing this issue, the evaluators chose to consider 
whether funding the ight against the diseases is achieved at 
the expense of funding for other health system initiatives, 
 including mother and child healthcare. Hence, has the ques-
tion regarding the systemic effects of Global Fund funding 
been properly asked?
In providing massive funding for the ight against these 
diseases, the underlying assumption was that improving the 
ability to control them would de facto strengthen health 
 systems. Does experience do anything to dent this assum-
ption? To what degree does the evaluation attempt to answer 
this question? In the literature, responses vary (9-11). To 
 arrive at an answer, it would be essential to analyze the 
 repercussions of Global Fund funding or innovative funding 
such as that provided by Unitaid (www.unitaid.eu) on 
 country-level  systems for the provision and distribution of 
medications (for example).
More globally, in environments where there are more 
and more patients and fewer and fewer medical staff (12), 
and where severe shortages of equipment and funding are 
the norm – which is the case in the majority of African 
countries – we must recognize that only a little is needed 
to keep poli tical attention and existing resources focused 
in favor of a handful of closely-monitored programs. To 
what extent does the Global Fund evaluation put forward 
practical proposals regarding the effects imposed by the 
lack of medical staff on the ability to achieve MDG 6? To 
what extent do the  systemic effects of Global Fund fund-
ing impact on the treatment of cardiovascular disease or 
chronic diseases such as diabetes and cancer, which are 
increasingly prevalent in countries where AIDS is not a 
national public health priority? These issues still need to 
be explored.
3.3 Challenges not addressed by the evaluation
Regarding the relevance of national and international 
strategies to combat the three diseases
At the time the Global Fund was set up, the main assump-
tion was that existing country-level strategies to control 
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AIDS, tuberculosis and malaria were relevant and  supported 
 tech nically by UNAIDS and the WHO, and that increasing 
the coverage of initiatives (facilitated by the availability of 
 additional funding) would ultimately restrict the spread and 
effects of these three pandemics.
Everybody who works on the front line knows that things 
are not that simple. The joint funding impact evaluation 
 analyses should have focused the minds of the evaluators, 
the evaluation steering committee and the Global Fund 
Board (to whom these analyses were intended) on the issues 
surrounding the relevance of its strategies, and particularly 
its AIDS prevention strategy.
The independent evaluations conducted by UNAIDS in 
2002 (13) and again in 2009 (14) hammer home the 
 message of how urgent it is to manage the AIDS pandemic 
more  effectively.
That is not what we see. At its Board meeting of May 
2009, the Global Fund was questioned about its responsi-
bility to invest strategically in the ight against AIDS (15). 
Some Board members asked for further work to be done to 
clarify their analyses. At the Board meeting held in Addis 
Ababa in November in the same year, the focus was no 
 longer on eva luation, but rather on the conference on re-
building Global Fund resources and the desire for the 
 commitment of billions of dollars in a tense atmosphere of 
global inancial crisis.  Although we understand the justii-
able necessity to maintain or increase the level of funding 
raised in order to move  forward towards universal access, 
we favor the revision of country-level strategies to make 
them more targeted, more speciic and more effective in 
 response to determining factors and country-level situations 
yet to be analyzed; thus raising the risk that inancial preoc-
cupation could once again take precedence over strategic 
eficiency. This is all the more  essential since a series of 
crises are destabilizing development aid efforts: the global 
crisis among healthcare professionals, the global inancial 
and economic crisis,  demographic growth, and climate 
change. Despite the appeals made by the World Bank to 
maintain the level of aid, particularly in favor of social 
 sectors, the continuation of funding for the therapeutic 
treatment of AIDS remains a very serious concern (16). The 
report published by the World Bank in April 2009 was 
 already warning that AIDS prevention and treatment 
 programs were being affected by the crisis (17). The irst 
 observations to emerge from a survey conducted in March 
2009 among 69 countries offering 3.4 million people basic 
antiretroviral treatment indicated that 8 of these countries 
were already very short of this type of medication, or were 
experiencing other problems that posed a risk of AIDS 
treatment suspension. A total of 22 African, Caribbean, 
 European, Central Asian and Paciic countries antici pated 
dificulties of this type during the year. Between them, these 
countries  accounted for more than 60% of  people world-
wide receiving treatment for AIDS. HIV  prevention pro-
grams were also compromised. In 34 countries together 
 accounting for 75% of people living with HIV, the 
 pre vention programs targeting high-risk groups ( especially 
sex workers and intravenous drug users) had  already 
been  impacted.
Regarding the identiication of bottlenecks  
to eficient use of Global Fund funding
None of the Global Fund evaluation studies reveal what we 
believe to be a major obstacle to the provision of funding and 
the extension of services: the low level of health sector capa-
city in tender management. This is a long-standing obstacle 
to the use of funding at levels equivalent to the loans and 
donations made by the World Bank, the French Development 
Agency and the European Commission, and is recognized by 
the European Court of Auditors to slow down the use of 
 funding (18). Truly practical procedures must be introduced 
to remove this obstacle, although this is not commented upon 
by the evaluators, which is all the more surprising given that 
purchases can account for more than 50% of the funding 
 provided by the Global Fund.
Is it up to the Global Fund to strengthen health systems?
In response to the assumptions made regarding the systems 
effects of Global Fund funding, we believe that the evalua-
tion did not ask the most important question: is it the duty 
of the Global Fund to strengthen health systems, since its 
vocation was to extend and accelerate initiatives specii-
cally  targeting the three diseases? At inception, the mandate 
of the Global Fund was to act quickly and massively to 
counter the pandemics and achieve MDG 6. That being the 
case, the steering committee and evaluators should have 
asked the question: how can we act fast to expand access to 
prevention and treatment in those areas where health sys-
tems are weak? It follows that in order to gear up quickly in 
terms of scale and speed, parallel systems of management, 
procurement, training, health information and program 
monitoring must, in the irst instance, be implemented only 
where justiied. This would certainly not have prevented 
countries from acting with the support of other international 
institutions, all of which are partners of the Global Fund 
(speciically the World Bank and the European Commis-
sion) to strengthen health systems at the same time as the 
Global Fund provided support for speciic activities. But we 
did not see that happening. This discrepancy, which is the 
cause of the imbalance seen today, relects primarily a 
 failure of the Global Fund partnership model, both at the 
 global level and the country level. It also relects the lack of 
interest among policy-makers and publicly-funded devel-
opment aid institutions: the bilateral initiatives undertaken 
by the European Commission and France in West and 
 Central Africa have shrunk substantially as a result of the 
majority of their funding being allocated to global health 
initiatives (especially those run by the Global Fund, GAVI 
Alliance and UNITAID). This precisely overlooks the fact 
that it is via these initiatives that the ight against the dis-
eases is predominantly planned and funded. At the same 
time, World Bank funding for health systems is also dimin-
ishing. All these choices have resulted in an imbalance in 
favor of the diseases, to the point where they account for an 
quivalent, and in some cases larger, proportion of health 
ministry budgets in several Sub-Saharan countries (18 and 
19). It is, however, recognized by the European Court of 
 Auditors that the funding instruments of the European 
 Development Fund (including variable tranche budgetary 
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aid  packages8 and sector-targeted aid) are applied to fund 
health system strengthening initiatives (18); a sector in 
which the European Parliament wishes to see a stronger 
 exercise of  political will from the European Union and the 
 Commissioners for External Relations and Development 
(20). These  inancial instruments (general budget support 
and sector  budget  support), which are preferred by the 
World Bank, the United Kingdom and even the French 
 Development Agency, are equally well suited to systemic 
approaches. It is therefore important to work on the basis 
of synergy at global and country levels, which was the 
 insistent recommendation of the 2005 Paris Declaration on 
Aid Effectiveness and Harmonisation9 and the EU Code of 
 Conduct on Complementarity and the Division of Labour 
in Development Policy (21).
The logical outcome is that current collaborative efforts 
 between the WHO, the World Bank, the GAVI Alliance and 
the Global Fund to address the issue of strengthening health 
systems must be extended to include the contribution of the 
European Commission, which provides high levels of fund-
ing in Africa and the Caribbean and Paciic (ACP) zones 
most  affected by the AIDS pandemic, and must certainly 
 extend to include British cooperation. Our view is that global 
public/private partnerships whose current and future innova-
tive funding may form part of these discussions on the 
strengthening of health systems are neither mandated nor 
best placed to become leaders in terms of health system 
strengthening. We must not lose sight of the fact that this 
 responsibility lies primarily with the countries themselves, 
supported by the WHO and development partners that have 
recommended the kind of systemic approach that is more the 
remit of bilateral aid.
Regarding the identiication, mobilization and funding of 
technical expertise to support Global Fund projects
The need for health sector technical expertise is a universal 
issue for fund providers: the European Court of Auditors 
 deplores the absence of a policy to cover expert resources 
and the strengthening of country-level capacity in the 
 context of European public funding of development aid 
(22); we are witnessing a decline in the provision of French 
technical  assistance to support the health sector in Africa 
(23); there is a lack of training and development facilities 
for this type of expertise, both nationally and internationally 
(24). The  second study area of the Global Fund ive-year 
evaluation stresses the fact that the ‘technical assistance’ 
 issue should be tackled collectively as part of country-level 
and international partnerships. We view as vital that new 
expertise be brought forward at country and international 
levels, and that this expertise be tailored to support the new 
health sector funding instruments of developing countries 
(25). We believe that as major donors to the Global Fund 
 8 The grant agreement speciies the rate at which non-targeted budget-
ary aid tranches are paid. The variable tranches are supposed to be paid 
in addition on the basis of the performance of social sectors measured 
using indicators deined in cooperation with the country concerned.
 9 http://www.oecd.org/dac/effectiveness
with seats on its governing board, France and the European 
Union have a particular  responsibility in this respect, espe-
cially towards French-speaking countries, which found it 
harder to access information, guidelines and funding 
 during the period 2002-2009. The ‘Backup Initiative’ tech-
nical  assistance model introduced by the GTZ (website: 
http://www.gtz.de/en) to support Global Fund programs at 
the country level may inspire these developments. All 
partners agree that this is a vital issue, but to which extent 
do they discuss it in purely practical terms? What are the 
partners proposing? Where in Europe and  Africa are the 
future  global health experts being trained?
Equity of access to resources, information and knowledge
The evaluators are fairly clear on the fact that the distribu-
tion of Global Fund resources relative to population size or 
to the number of people affected by HIV is not rational. We 
note that the Global Fund is no exception in this respect, 
since authors comment on the fact that funding is not evi-
dence-based and speak of global health misinancing (26). 
Furthermore, the evaluation does not answer this question: 
have all these grants brought about any reduction in user 
fees, or any reduction in health-related poverty? Finding the 
answer could provide an excellent research project.
A more subtle disparity that may strike French-speaking 
readers of all these evaluation reports regards the differ-
ences between West & Central Africa on the one hand, and 
East and Southern Africa on the other, which emerges when 
one reads between the lines. The report on the third study 
makes it clear that the countries of West Africa received less 
 funding than those of East Africa, “due partly to the fact that 
their epide mics are less widespread”. It remains to be seen 
 whether the difference in the spread of the epidemic in itself 
justiies this unequal distribution of Global Fund resources 
between two parts of the same continent. This issue deser-
ved more  research work and analysis. There are clearly ‘pet 
countries’ that  receive conspicuous attention from many 
fund providers. These include Zambia, Mozambique and 
Uganda. No doubt they have learned how to deliver and 
demonstrate the  required performance. From the point of 
view of public health, we  believe it equally fair and justiied 
to take a closer interest in the countries experiencing 
 dificulties. These studies should also have focused on 
 examining whether the less impressive results hinted at by 
the evaluators in West and Central  Africa10 were related to 
any lack of access to resources (information, knowledge, 
 expertise and funding).
Ever since the beginning of the AIDS pandemic, the French-
speaking countries of Africa have found it more  dificult to 
access information, documents, guidelines, bibliographic 
 references, research indings, and so on, since all these docu-
ments were originally (and sometimes only)  published in 
 English, regardless of whether they were prepared by the 
WHO, UNAIDS, the Global Fund or any other partner. The 
calls for clinical research projects launched by the EDCTP 
 10 Commented upon verbally in evaluation steering committee ses-
sions and visible on reading the evaluation reports for certain countries.
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program funded by the European Commission11 have  remained 
in English for too long, making access to them unfair for 
French-speaking African research teams over  several years, 
when this European funding is supposed to beneit research 
teams throughout the continent. The grant agreements issued 
by the Global Fund are drafted in English, even where they are 
used in French-speaking countries. The program monitoring/
evaluation guide is a very valuable  technical resource for 
those active at the local level, but it is available only in English 
(27). The Global Fund ive-year evaluation reports are 
 available only in English. Why deprive so many French-
speaking local workers and universities of the opportunity to 
access the knowledge and learning that could be obtained by 
reading these documents in detail? The same applies to 
 Spanish speakers and Portuguese speakers, among others.
As the European Commission, France, Germany and the 
World Bank reduced their investment in the West African 
health sector throughout the irst decade of the 21st century, 
the countries of eastern and southern Africa have  beneited 
from more recent political commitments and massive 
 development aid funding from Britain, the Ame rican 
 presidential PEPFAR program, and private funding from the 
Bill and  Melinda Gates Foundation, as well as very large 
contributions from the European Commission ( Zambia) and 
the  Global Fund to ight AIDS, Tuberculosis and  Malaria. 
We consider that it is vital that a retrospective study into 
this unequal distribution of resources be conducted at the 
 earliest opportunity so that measures can be put in place to 
limit the risk of its continuation.
There is an urgent need to reconsider the overall distri-
bution of resources available to support the health sector 
throughout the African continent, and at the global scale. 
We see this as one of the component parts of analyzing the 
 architecture and effectiveness of aid.
4 Conclusions
The evaluation raises, and in some cases fails to raise, a 
 number of issues that the Global Fund Board would do well 
to consider. The most important for the community of fund 
providers is that surrounding the real country-level impact of 
the sums attracted and committed, which are totally unpre-
cedented. With this in mind, it is important to be very clear 
about the position of the Global Fund’s public/private part-
nership stakeholders, at least regarding the following issues, 
which have a direct bearing on funding:
(i) the revision of AIDS prevention strategies, without 
omitting to provide broad-based funding for every 
 element of prevention, such as safe blood and transfu-
sion, the diagnosis and early treatment of STIs and the 
prevention of mother to child transmission of HIV 
through a commitment to improve the level of use of 
maternal health services, all effective and eficient 
 intervention strategies, although they receive little 
 11 www.edctp.org, European and Developing countries Clinical Trials 
Partnership (website in English only).
funding from individual countries and the interna-
tional community, especially the Global Fund, whose 
earmarked funding for HIV prevention is 4% for 
blood safety, 6% for the diagnosis and early treatment 
of STIs, and 15% for the prevention of mother/child 
HIV transmission12.
(ii) the strengthening of health systems in all their aspects, 
but especially basic health services, in order to facili-
tate the expansion and decentralization of prevention 
and treatment services for the three diseases.
(iii) the training, mobilization and funding by countries 
and the international partner institutions of the  Global 
Fund of high-level technical and managerial exper-
tise in order to support: a) an improvement in the 
 sub- recipients’ capacity to  implement Global Fund 
 programs, and b) the  country-level implementation of 
new health sector funding methods, including 
 innovative funding.
(iv) practical methods for synergy-based co-operative 
working between country-level contributors in 
 accordance with the provisions of the EU Code of 
Conduct on Complementarity and the Division of 
 Labour in Development and the Paris Declaration 
on Aid  Effectiveness and Harmonisation13.
The performance and success of Global Fund funding in 
achieving MDG 6 will depend on the consideration and 
 practical commitments given by Global Fund partners in 
all these areas as part of in-depth Board discussions, 
 bearing in mind the partner commitments restated at the 
G8 meeting in Italy to pay more attention to the effective-
ness of initiatives (28). Their discussions will be all the 
more productive and useful in supporting existing or future 
 innovative funding at the global scale, whether for health 
or other sectors, such as food security, climate change, etc. 
France and Europe must demonstrate that they are equal to 
the challenges raised by the revolutions now underway in 
the architecture of inter national aid (29), assume their 
rightful place and exert their  inluence (30) to extend in a 
new form their respective,  historically-concerted and 
 recognized contributions to the epic challenge of interna-
tional health cooperation.
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